Report cover image

Central Nervous System (CNS) Therapeutics Industry Research Report 2025

Publisher APO Research, Inc.
Published Jul 06, 2025
Length 121 Pages
SKU # APRC20261311

Description

Summary

According to APO Research, The global Central Nervous System (CNS) Therapeutics market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Central Nervous System (CNS) Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Central Nervous System (CNS) Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Central Nervous System (CNS) Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Central Nervous System (CNS) Therapeutics include Biogen, UCB Pharma, Viatris, Eli Lilly, Roche, Merck & Co Inc, Novartis, Johnson and Johnson and Teva and etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Central Nervous System (CNS) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Central Nervous System (CNS) Therapeutics.

The Central Nervous System (CNS) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Central Nervous System (CNS) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Central Nervous System (CNS) Therapeutics Segment by Company

Biogen
UCB Pharma
Viatris
Eli Lilly
Roche
Merck & Co Inc
Novartis
Johnson and Johnson
Teva
Takeda
Central Nervous System (CNS) Therapeutics Segment by Type

CNS Trauma
Neurovascular Diseases
Neurodegenerative Diseases
Other
Central Nervous System (CNS) Therapeutics Segment by Application

Hospital
Online
Other
Central Nervous System (CNS) Therapeutics Segment by Application

Hospital
Online
Other
Central Nervous System (CNS) Therapeutics Segment by Region


North America
United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Central Nervous System (CNS) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Central Nervous System (CNS) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Central Nervous System (CNS) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Central Nervous System (CNS) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

121 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Central Nervous System (CNS) Therapeutics by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 CNS Trauma
2.2.3 Neurovascular Diseases
2.2.4 Neurodegenerative Diseases
2.2.5 Other
2.3 Central Nervous System (CNS) Therapeutics by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Hospital
2.3.3 Online
2.3.4 Other
2.4 Assumptions and Limitations
3 Central Nervous System (CNS) Therapeutics Breakdown Data by Type
3.1 Global Central Nervous System (CNS) Therapeutics Historic Market Size by Type (2020-2025)
3.2 Global Central Nervous System (CNS) Therapeutics Forecasted Market Size by Type (2026-2031)
4 Central Nervous System (CNS) Therapeutics Breakdown Data by Application
4.1 Global Central Nervous System (CNS) Therapeutics Historic Market Size by Application (2020-2025)
4.2 Global Central Nervous System (CNS) Therapeutics Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Central Nervous System (CNS) Therapeutics Market Perspective (2020-2031)
5.2 Global Central Nervous System (CNS) Therapeutics Growth Trends by Region
5.2.1 Global Central Nervous System (CNS) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Central Nervous System (CNS) Therapeutics Historic Market Size by Region (2020-2025)
5.2.3 Central Nervous System (CNS) Therapeutics Forecasted Market Size by Region (2026-2031)
5.3 Central Nervous System (CNS) Therapeutics Market Dynamics
5.3.1 Central Nervous System (CNS) Therapeutics Industry Trends
5.3.2 Central Nervous System (CNS) Therapeutics Market Drivers
5.3.3 Central Nervous System (CNS) Therapeutics Market Challenges
5.3.4 Central Nervous System (CNS) Therapeutics Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Central Nervous System (CNS) Therapeutics Players by Revenue
6.1.1 Global Top Central Nervous System (CNS) Therapeutics Players by Revenue (2020-2025)
6.1.2 Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Players (2020-2025)
6.2 Global Central Nervous System (CNS) Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Central Nervous System (CNS) Therapeutics Head Office and Area Served
6.4 Global Central Nervous System (CNS) Therapeutics Players, Product Type & Application
6.5 Global Central Nervous System (CNS) Therapeutics Manufacturers Established Date
6.6 Global Central Nervous System (CNS) Therapeutics Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Central Nervous System (CNS) Therapeutics Market Size (2020-2031)
7.2 North America Central Nervous System (CNS) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Central Nervous System (CNS) Therapeutics Market Size by Country (2020-2025)
7.4 North America Central Nervous System (CNS) Therapeutics Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Central Nervous System (CNS) Therapeutics Market Size (2020-2031)
8.2 Europe Central Nervous System (CNS) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Central Nervous System (CNS) Therapeutics Market Size by Country (2020-2025)
8.4 Europe Central Nervous System (CNS) Therapeutics Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size (2020-2031)
9.2 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size by Country (2020-2025)
9.4 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Central Nervous System (CNS) Therapeutics Market Size (2020-2031)
10.2 South America Central Nervous System (CNS) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Central Nervous System (CNS) Therapeutics Market Size by Country (2020-2025)
10.4 South America Central Nervous System (CNS) Therapeutics Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size (2020-2031)
11.2 Middle East & Africa Central Nervous System (CNS) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size by Country (2020-2025)
11.4 Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Biogen
12.1.1 Biogen Company Information
12.1.2 Biogen Business Overview
12.1.3 Biogen Revenue in Central Nervous System (CNS) Therapeutics Business (2020-2025)
12.1.4 Biogen Central Nervous System (CNS) Therapeutics Product Portfolio
12.1.5 Biogen Recent Developments
12.2 UCB Pharma
12.2.1 UCB Pharma Company Information
12.2.2 UCB Pharma Business Overview
12.2.3 UCB Pharma Revenue in Central Nervous System (CNS) Therapeutics Business (2020-2025)
12.2.4 UCB Pharma Central Nervous System (CNS) Therapeutics Product Portfolio
12.2.5 UCB Pharma Recent Developments
12.3 Viatris
12.3.1 Viatris Company Information
12.3.2 Viatris Business Overview
12.3.3 Viatris Revenue in Central Nervous System (CNS) Therapeutics Business (2020-2025)
12.3.4 Viatris Central Nervous System (CNS) Therapeutics Product Portfolio
12.3.5 Viatris Recent Developments
12.4 Eli Lilly
12.4.1 Eli Lilly Company Information
12.4.2 Eli Lilly Business Overview
12.4.3 Eli Lilly Revenue in Central Nervous System (CNS) Therapeutics Business (2020-2025)
12.4.4 Eli Lilly Central Nervous System (CNS) Therapeutics Product Portfolio
12.4.5 Eli Lilly Recent Developments
12.5 Roche
12.5.1 Roche Company Information
12.5.2 Roche Business Overview
12.5.3 Roche Revenue in Central Nervous System (CNS) Therapeutics Business (2020-2025)
12.5.4 Roche Central Nervous System (CNS) Therapeutics Product Portfolio
12.5.5 Roche Recent Developments
12.6 Merck & Co Inc
12.6.1 Merck & Co Inc Company Information
12.6.2 Merck & Co Inc Business Overview
12.6.3 Merck & Co Inc Revenue in Central Nervous System (CNS) Therapeutics Business (2020-2025)
12.6.4 Merck & Co Inc Central Nervous System (CNS) Therapeutics Product Portfolio
12.6.5 Merck & Co Inc Recent Developments
12.7 Novartis
12.7.1 Novartis Company Information
12.7.2 Novartis Business Overview
12.7.3 Novartis Revenue in Central Nervous System (CNS) Therapeutics Business (2020-2025)
12.7.4 Novartis Central Nervous System (CNS) Therapeutics Product Portfolio
12.7.5 Novartis Recent Developments
12.8 Johnson and Johnson
12.8.1 Johnson and Johnson Company Information
12.8.2 Johnson and Johnson Business Overview
12.8.3 Johnson and Johnson Revenue in Central Nervous System (CNS) Therapeutics Business (2020-2025)
12.8.4 Johnson and Johnson Central Nervous System (CNS) Therapeutics Product Portfolio
12.8.5 Johnson and Johnson Recent Developments
12.9 Teva
12.9.1 Teva Company Information
12.9.2 Teva Business Overview
12.9.3 Teva Revenue in Central Nervous System (CNS) Therapeutics Business (2020-2025)
12.9.4 Teva Central Nervous System (CNS) Therapeutics Product Portfolio
12.9.5 Teva Recent Developments
12.10 Takeda
12.10.1 Takeda Company Information
12.10.2 Takeda Business Overview
12.10.3 Takeda Revenue in Central Nervous System (CNS) Therapeutics Business (2020-2025)
12.10.4 Takeda Central Nervous System (CNS) Therapeutics Product Portfolio
12.10.5 Takeda Recent Developments
13 Report Conclusion
14 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.